CN118159562A - 靶向ccr2的抗体 - Google Patents

靶向ccr2的抗体 Download PDF

Info

Publication number
CN118159562A
CN118159562A CN202280072046.7A CN202280072046A CN118159562A CN 118159562 A CN118159562 A CN 118159562A CN 202280072046 A CN202280072046 A CN 202280072046A CN 118159562 A CN118159562 A CN 118159562A
Authority
CN
China
Prior art keywords
antibody
seq
human
ccr2
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280072046.7A
Other languages
English (en)
Chinese (zh)
Inventor
马蒂亚斯·马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Granite Biotechnology Co ltd
Original Assignee
Granite Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Granite Biotechnology Co ltd filed Critical Granite Biotechnology Co ltd
Publication of CN118159562A publication Critical patent/CN118159562A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280072046.7A 2021-10-27 2022-10-25 靶向ccr2的抗体 Pending CN118159562A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21204904 2021-10-27
EP21204904.3 2021-10-27
PCT/EP2022/079744 WO2023072916A1 (en) 2021-10-27 2022-10-25 Antibodies targeting ccr2

Publications (1)

Publication Number Publication Date
CN118159562A true CN118159562A (zh) 2024-06-07

Family

ID=78413745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280072046.7A Pending CN118159562A (zh) 2021-10-27 2022-10-25 靶向ccr2的抗体

Country Status (10)

Country Link
US (2) US12168692B1 (https=)
EP (1) EP4423131A1 (https=)
JP (1) JP2024540196A (https=)
KR (1) KR20240099211A9 (https=)
CN (1) CN118159562A (https=)
AU (1) AU2022378899A1 (https=)
CA (1) CA3231124A1 (https=)
IL (1) IL311476A (https=)
MX (1) MX2024004447A (https=)
WO (1) WO2023072916A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245988A1 (en) * 2023-05-29 2024-12-05 Granite Bio Ag Antibodies targeting ccr2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE102006015341A1 (de) 2006-04-03 2007-10-04 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
JP5685535B2 (ja) 2008-08-18 2015-03-18 ファイザー インコーポレイティッド Ｃｃｒ２に対する抗体
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
EP2727944A1 (en) * 2012-10-30 2014-05-07 Universitätsklinikum Regensburg Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system
WO2016079276A1 (en) 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease

Also Published As

Publication number Publication date
US20240392018A1 (en) 2024-11-28
AU2022378899A1 (en) 2024-03-07
MX2024004447A (es) 2024-05-08
KR20240099211A (ko) 2024-06-28
US12168692B1 (en) 2024-12-17
JP2024540196A (ja) 2024-10-31
WO2023072916A1 (en) 2023-05-04
KR20240099211A9 (ko) 2025-12-10
EP4423131A1 (en) 2024-09-04
CA3231124A1 (en) 2023-05-04
IL311476A (en) 2024-05-01
US20250059288A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
CN111601825B (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
EP4393950A1 (en) Fap/cd40 binding molecule and medicinal use thereof
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
TW202448940A (zh) 結合介白素4受體α之抗體及其使用方法
TW202509068A (zh) 結合ox40l之抗體及使用方法
US20250059288A1 (en) Antibodies targeting ccr2
US20250382362A1 (en) Antibodies targeting il3
CN111788229A (zh) Csf1r结合剂
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
HK40111251A (zh) 靶向ccr2的抗体
EP4585618A1 (en) Anti-ilt4 antibody and pharmaceutical use thereof
CN121399160A (zh) 靶向ccr2的抗体
WO2026067827A1 (zh) 一种制备异源多聚体的方法及应用
TW202602945A (zh) 抗ｇｕｃｙ２ｃ抗體及其多特異性抗體的用途
WO2026008055A1 (zh) 抗kit抗体及其医药用途
CN121226557A (zh) 抗cMET抗体
CN121226555A (zh) 抗cMET抗体
CN121270705A (zh) 抗cMET抗体
CN120476145A (zh) 靶向cd45的抗体
HK40034272B (en) Fully human anti-b cell maturation antigen (bcma) single chain variable fragment, and application thereof

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111251

Country of ref document: HK